Glucocorticoids remain the first-line therapy, but their use carries a dose-dependent risk of severe adverse events (40)
Lipotropic injections are generally not recommended during pregnancy or breastfeeding, for people with a known allergy to any component of the formulation (including B12/cobalt), for those with certain kidney or liver conditions, or for those with certain medical conditions
While some jurisdictions allow the unrestricted purchase of such substances for laboratory use, others might impose restrictions
Phase 3 data places retatrutides average weight reduction at approximately 28%, versus tirzepatides approximately 22.5% [2]
"It was not lifestyle management versus GLP-1
9) Romero DL, Mounho BJ, Lauer FT, Born JL, Burchiel SW